BioCentury | Jul 20, 2015
Strategy

Window to gene therapy

...also had a 2002 deal for adenoviral vector development and manufacturing services with the now-defunct Introgen Therapeutics Inc....
BioCentury | Apr 15, 2013
Company News

IntroGene sales and marketing update

IntroGene said that its PER.C6 packaging cell line to produce adenoviral vectors is available for commercialization with collaborative partners. PER.C6 incorporates primary human embryonic retinoblasts with an E1 mini gene of human adenovirus type 5....
BioCentury | Apr 15, 2013
Company News

Introgen management update

Introgen Therapeutics Inc. , Austin, Texas Business: Cancer Hired: Shawn Gallagher, vice president of manufacturing; formerly director of operations at Magenta Corp. WIR Staff cancer...
BioCentury | Apr 15, 2013
Company News

Introgen, Rhone-Poulenc Rorer deal

...trials of p53 in Europe for head, neck and hepatocellular cancers. Pending a review of Introgen's...
...also has manufacturing rights in Europe and other markets. Introgen retains North American manufacturing rights. Introgen Therapeutics Inc....
BioCentury | Apr 11, 2011
Finance

A Remembrance: The venture capitalist as artist

A Remembrance: The venture capitalist as artist Jean Deleage was one of the privileged few who could count many firsts in his life. But he didn't just help start the biotech industry and then ride...
BioCentury | May 31, 2010
Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
BioCentury | Feb 8, 2010
Product Development

Checking the boxes in gene therapy

...efficacy or safety in clinical trials. In 2008, FDA refused to file a BLA from Introgen Therapeutics Inc....
...compared to methotrexate in the Phase III T301 trial (see BioCentury, June 2, 2008) . Introgen...
...Calif. Amsterdam Molecular Therapeutics , Amsterdam, the Netherlands Ark Therapeutics Group plc (LSE:AKT), London, U.K. Introgen Therapeutics Inc....
BioCentury | Aug 10, 2009
Clinical News

Contusugene ladenovec regulatory update

...EMEA said Introgen withdrew an MAA for Contusugene ladenovec to treat squamous cell carcinoma of the...
...to treat squamous cell carcinoma of the head and neck (SCCHN). According to the agency, Introgen...
...on its "difficult financial situation." The company filed for Chapter 11 bankruptcy in late 2008. Introgen...
BioCentury | Apr 20, 2009
Finance

Cancer vaccine uplift

...Inc. (NASDAQ:CEGE) $0.49 53% ImmunoCellular Therapeutics Ltd. (OTCBB:IMUC) $0.37 48% Antigenics Inc. (NASDAQ:AGEN) $0.65 44% Introgen Therapeutics Inc....
BioCentury | Jan 5, 2009
Clinical News

Advexin regulatory update

...EMEA said Introgen withdrew an MAA for Advexin to treat Li-Fraumeni syndrome (LFS) cancers. According to...
...withdrew an MAA for Advexin to treat Li-Fraumeni syndrome (LFS) cancers. According to the agency, Introgen...
...FDA refused to file a BLA for Advexin for SCCHN (see BioCentury, Sept. 8, 2008). Introgen Therapeutics Inc....
Items per page:
1 - 10 of 312
BioCentury | Jul 20, 2015
Strategy

Window to gene therapy

...also had a 2002 deal for adenoviral vector development and manufacturing services with the now-defunct Introgen Therapeutics Inc....
BioCentury | Apr 15, 2013
Company News

IntroGene sales and marketing update

IntroGene said that its PER.C6 packaging cell line to produce adenoviral vectors is available for commercialization with collaborative partners. PER.C6 incorporates primary human embryonic retinoblasts with an E1 mini gene of human adenovirus type 5....
BioCentury | Apr 15, 2013
Company News

Introgen management update

Introgen Therapeutics Inc. , Austin, Texas Business: Cancer Hired: Shawn Gallagher, vice president of manufacturing; formerly director of operations at Magenta Corp. WIR Staff cancer...
BioCentury | Apr 15, 2013
Company News

Introgen, Rhone-Poulenc Rorer deal

...trials of p53 in Europe for head, neck and hepatocellular cancers. Pending a review of Introgen's...
...also has manufacturing rights in Europe and other markets. Introgen retains North American manufacturing rights. Introgen Therapeutics Inc....
BioCentury | Apr 11, 2011
Finance

A Remembrance: The venture capitalist as artist

A Remembrance: The venture capitalist as artist Jean Deleage was one of the privileged few who could count many firsts in his life. But he didn't just help start the biotech industry and then ride...
BioCentury | May 31, 2010
Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
BioCentury | Feb 8, 2010
Product Development

Checking the boxes in gene therapy

...efficacy or safety in clinical trials. In 2008, FDA refused to file a BLA from Introgen Therapeutics Inc....
...compared to methotrexate in the Phase III T301 trial (see BioCentury, June 2, 2008) . Introgen...
...Calif. Amsterdam Molecular Therapeutics , Amsterdam, the Netherlands Ark Therapeutics Group plc (LSE:AKT), London, U.K. Introgen Therapeutics Inc....
BioCentury | Aug 10, 2009
Clinical News

Contusugene ladenovec regulatory update

...EMEA said Introgen withdrew an MAA for Contusugene ladenovec to treat squamous cell carcinoma of the...
...to treat squamous cell carcinoma of the head and neck (SCCHN). According to the agency, Introgen...
...on its "difficult financial situation." The company filed for Chapter 11 bankruptcy in late 2008. Introgen...
BioCentury | Apr 20, 2009
Finance

Cancer vaccine uplift

...Inc. (NASDAQ:CEGE) $0.49 53% ImmunoCellular Therapeutics Ltd. (OTCBB:IMUC) $0.37 48% Antigenics Inc. (NASDAQ:AGEN) $0.65 44% Introgen Therapeutics Inc....
BioCentury | Jan 5, 2009
Clinical News

Advexin regulatory update

...EMEA said Introgen withdrew an MAA for Advexin to treat Li-Fraumeni syndrome (LFS) cancers. According to...
...withdrew an MAA for Advexin to treat Li-Fraumeni syndrome (LFS) cancers. According to the agency, Introgen...
...FDA refused to file a BLA for Advexin for SCCHN (see BioCentury, Sept. 8, 2008). Introgen Therapeutics Inc....
Items per page:
1 - 10 of 312